Alloreactive cytotoxic T lymphocyte immunotherapy treatment of a patient with metastatic prostate cancer: A case report

RATIONALE: Cytotoxic T lymphocyte (CTL) immunotherapy is an autologous cellular immune therapy that has been approved for treating patients with malignant tumors. However, there is still limited information regarding the impact of CTL on metastatic prostate cancer (PC) patients with bone metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Junfeng, Chen, Yi, Chen, Yuetong, Shen, Yunzhu, Zhao, Huanyu, Sun, Hui, Chen, Jinfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023702/
https://www.ncbi.nlm.nih.gov/pubmed/29901632
http://dx.doi.org/10.1097/MD.0000000000011111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023702/
https://www.ncbi.nlm.nih.gov/pubmed/29901632
http://dx.doi.org/10.1097/MD.0000000000011111

Ejemplares similares